Web🧬En el consorcio #OLIGOFASTX aprovechamos el mecanismo de los siRNAs para el desarrollo de terapias basadas en #oligonucleótidos. ⬇️ ¿Quieres saber más?… WebOligofastx is a project born from a need: to offer a therapeutic pathway based on the development of specific oligonucleotides for certain rare diseases for which there is no …
OLIGOFASTX consortium shares at Farmaforum the progress of …
WebPROJECT OLIGOFASTX. Ref: MIG-20241028. OLIGOFASTX is a multidisciplinary consortium made up of two companies considered to be large companies Sylentis (PharmaMar Group), Nanovex (QuĂmica del NalĂłn Industrial Group) and five independent SMEs (AptusBiotech, AptaTargets, Arthex, Nostrum Biodiscovery and Biotechnology … Web09. jun 2024. · We are delighted to present #OLIGOFASTX: a multidisciplinary consortium led by #Sylentis (from @PhrmMar) and formed by Spanish companies: … joey catchphrase
ABOUT OLIGOFASTX - Oligofastx
Web09. sep 2024. · “👩🔬Judith Walker ( @arthex ) is at the 👉Myotonic Dystrophy Foundation Annual Conference presenting the development of their lead compound ATX-01, and the … Web24. mar 2024. · 53Biologics participates in the OLIGOFASTX project. This project aims to create a comprehensive platform to facilitate and contribute to the accelerated development of oligonucleotide-based therapies in Spain. OLIGOFASTX is a multidisciplinary consortium led by Sylentis (PharmaMar Group) and in which other companies such as Nanovex ... WebConsorcio de 7 empresas españolas crean OLIGOFASTX, una plataforma sostenible para el desarrollo de terapias basadas en ARN. Publicado el 2 de febrero de 2024 5 de julio de 2024 por sylentis. 02 Feb. joey cathcart